Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1893 Zika vaccine in adults
NCT04917861Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of mRNA-1893 in Zika virus infection (4 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Reactogenicity Adverse Reactions at 7 days, Unsolicited Adverse Events at 28 days and 6 more. Started Jun 2021; status: completed.
02
Drugs
mRNA-1893
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT04917861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917861.